NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.
NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
Please login or register first to view this content.
